2018
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original Research
2012
Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study.
Sinclair N, Abu-Khalaf M, Rizack T, Rosati K, Chung G, Legare R, DiGiovanna M, Fenton M, Bossuyt V, Strenger R, Sakr B, Lannin D, Gass J, Harris L, Sikov W. Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study. Journal Of Clinical Oncology 2012, 30: 1045-1045. DOI: 10.1200/jco.2012.30.15_suppl.1045.Peer-Reviewed Original ResearchResidual cancer burdenCR/PRTriple-negative breast cancerAnthracycline-based therapyWeekly nab-paclitaxelSerious adverse eventsLonger treatment durationAUC 6Doxorubicin-cyclophosphamideInvasive BRCANeutropenic feverNSABP BWeekly paclitaxelGI bleedNab-paclitaxelAdverse eventsAxillary nodesPartial responseSystemic therapyCancer burdenCohort 2Cohort 1Breast cancerGrade 3BRCA patients